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Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a well-known
neuropeptide, which also has vasomotor effects. However, little is known
regarding its age-related and organ-specific vasomotor effects. We
hypothesized that the vasomotor effects of PACAP depend on the tissue
origin of the vessels and aging substantially modulates its actions. Thus,
carotid (CA) and basilar arteries (BA) were isolated from young (2 months
old), middle age (12 months old), and old (30 months old) rats. Their
vasomotor responses were measured with an isometric
myograph (DMT610M)  in response to cumulative concentrations of
PACAP1-38 (10 –10  M). PACAP1-38 induced (1) a significantly greater
concentration-dependent relaxations in CA compared to that of BA of young,
middle age, and old rats; (2) relaxations of CA significantly decreased,
whereas it theydid not change substantially in BA, as a function of age; (3)
sodium nitroprusside (SNP)-induced relaxation did not change after
PACAP1-38 administration in any conditions; and (4) inhibition of PAC1
receptors by selective PAC1 receptor blocker (PACAP6-38) completely
diminished the responses to PACAP in all age groups of BA and CA. In
conclusion, these findings suggest that PACAP1-38 has greater vasomotor
effect in CA than that in BA, whereas aging has less effect on PACAP-
induced relaxation of cerebral arteries and BA than that in peripheral arteries
and CA suggesting that the vasomotor role ofrelaxation to PACAP is
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Introduction
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a well-known
neuropeptide with widespread organ and tissue distribution. The two
biologically active forms (PACAP1-38 and PACAP1-27) are important
neuroendocrine regulators of many biological systems, including the
cardiovascular system (Okazaki et al. 1992 ; Suzuki et al. 1993 ; Somogyvári-
Vigh and Reglődi 2004 ). The vascular actions of PACAP1-38 are more
effective compared to those of PACAP1-27 (Huang et al. 1992 ; Okazaki et al.
1992 ). The vasodilator activity of PACAP has been documented in vessels of
various organs (Nandha et al. 1991 ; Ross-Ascuitto et al. 1993 ) via three
specific receptors (PAC1R and VPAC1R/VPAC2R), both of which are highly
expressed in the cerebral and peripheral blood vessels (Fahrenkrug et al. 2000 ;
Nandha et al. 1991 ). They are localized in the smooth muscle cells of cerebral
arteries and arterioles (Fahrenkrug et al. 2000 ; Amenta et al. 1991 ). In vivo
studies on beagle dogs described that intravenous infusion of very low doses
(0.01–10 pmol/min) of PACAP induced a concentration-dependent increase in
blood flow in human skin and a concomitant decrease in systemic blood
pressure (Cardell et al. 1991 ; Nandha et al. 1991 ; Naruse et al. 1993 ). High
doses (>3 nmol) of PACAP elicited a biphasic effect: a transient hypotensive
response, followed by a sustained period of hypertension (Ishizuka et al. 1992 ;
Cardell et al. 1991 ). It was suggested that the action of PACAP on the vascular
tone could be ascribed both to a direct relaxant effect and an indirect
vasopressor action mediated through the release of endogenous catecholamines
(Cardell et al. 1991 ). In vivo studies of cats showed that PACAP
administration had a pressor effect in the hindquarters and PACAP increased
pulmonary vascular resistance, which was explained by the systemic release of
catecholamines from the adrenal gland (Minkes et al. 1992 ; Moller and Sundler
1996 ; Nogi et al. 1997 ). In vitro isolated vessel studies (Whalen et al. 1999 )
described that the dilator effects (measured by isotonic myograph) of PACAP
were due to its actions on the small arterioles, rather than the release of adrenal
catecholamines. These vessels were isolated, and this vasodilation—increasing
the diameter—may not involve the release of endothelium-derived nitric oxide
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(NO) (Vaudry et al. 2000 ). Previous studies have also shown that PACAP
receptors are present in various organs (Cardell et al. 1991 ) and also in vessels,
including intracerebral (Vaudry et al. 2000 ) and extracerebral arteries (Miyata
et al. 1998 ; Amenta et al. 1991 ), mesenteric, porcine coronary arteries
(Cardell et al. 1991 ), pulmonary vascular bed of rats (Minkes et al. 1992 ;
Cheng et al. 1993 ), and stem villous and intramyometrial arteries of humans
(Steenstrup et al. 1996 ). In spite of the numerous studies on the vascular
functions of PACAP, region-specific vasomotor actions are not well-
characterized. Aging has also been shown to greatly affect the vasomotor
function of vessels, which potentially contributes to organ dysfunction
(Tripathy et al 2010, Vamos et al. 2013, Ivic et al 2012 ). We thought that it
would be especially important to elucidate the effects of healthy aging on
PACAP-induced vasomotor regulation of basilar arteries, as PACAP is a
neuropeptide with potential vasomotor regulatory effect in the cerebrovascular
system.
In the present study, we hypothesized that PACAP has region-specific
vasomotor effects, which are substantially modulated by aging. Thus, we
characterized the concentration-dependent relaxations of carotid and basilar
arteries isolated from young (2 months old), middle age (12 months old), and




For these experiments, young (2 months old), middle age (12 months old), and
old (30 months old) male Wistar-Kyoto rats (WKY, N = 8, n = 16/per group of
age) were used (“N” for number of rats and “n” for number of vessels). All
procedures in the experiments were approved in accordance with the general
rules for animal protection in science work, a 2010 European Directive on
ethical issues (European Communities Council) Directive 2010/63/ECC and
Ethical Committee of the University for the Protection of Animals in Research




Isolation and Preparation of Carotid and Basilar Arteries
The vessels were isolated as previously described (Vamos et al. 2013 ; Toth et
al. 2011 ). In brief, animals were anesthetized by intraperitoneal ketamin and
decapitated immediately. The common carotid arteries (CA) and basilar arteries
(BA) were isolated from the rats, then cleaned and prepared under an Olympus
operation microscope, and quickly transferred into ice-cold (4 °C) oxygenated
(95 % O , 5 % CO ) Krebs’ buffer solution as described previously (Vamos et
al. 2013 ; Bagi et al. 2008 ). Then, BA and CA were dissected into 5-mm rings
and canulated by wires.
Isolation Vessel Measurements
Each artery was positioned between two stainless steel wires (diameter
0.04 mm) in a 5-mL organ bath of a small-vessel myograph (DMT 610 M,
Danish Myo Technology, Aarhus, Denmark). Isometric tension generated by
the vessels was continuously measured, and the software Myodaq 2.01 M610+
was used for data acquisition and display. At the beginning of experiments, the
length tension curve— (normalized to 2.0 g—) was obtained, and the vessels
were allowed to stabilize for 60 min according to experimental protocols
(Vamos et al. 2013 ). The bath solution was continuously oxygenated with a gas
mixture of 95 % O  plus 5 % CO  and kept at 36.8 °C (pH 7.4).
Administration of Vasoactive Agents
Vessels were allowed to stabilize for 60 min; then, to establish a tone, 60 mM
KCl was administered (Vamos et al. 2013 ). Vasomotor function of vessels was
studied in response to cumulative concentration of PACAP1-38, synthetized as
previously described (Jozsa et al. 2005 ), from 10  to10  mol/L. The intact
vasomotor function of smooth muscle was verified at the end of the experiment
by dilation to sodium nitroprusside (SNP; 10  to 10  mol/L). The age-
dependent changes in the vasomotor activity were measured by the difference
of PACAP1-38-induced isometric relaxation of BA and CA between 12- and
30-, 2- and 30-, and 2- and 12-month-old rats. Same protocols were repeated









Experimental results are presented as mean ± S.E.M. Statistical analysis was
performed by two-way ANOVA. To determine which groups differ from the
others, we have used the one-way ANOVA (Holm-Sidek, Tukey, Student-
Newman-Keuls) multiple comparison procedure by SPSS 11.0 for Windows
software. p Values <0.05 were considered to be statistically significant. Figures
were made by Sigma Plot 12.0 for Windows software.
Results
Effect of Cumulative Concentration-Dependent
Administration of PACAP1-38 on the Relaxation of Basilar
and Carotid Arteries as a Function of Age
Original records (Fig. 1 , panel a) show the relaxation of BA to the cumulative
doses of PACAP1-38. The relaxations did not change substantially from young
(2 months old—2 m), middle (12 months old—12 m), and old age (30 months
old—30 m). Steady-state values are the following: 2 m 10  M 5.17 mN,
10  M 4.7 mN, 10  M 4.58 mN, 10  M 4.56 mN; 12 m 10  M 4.56 mN,
10  M 4.35 mN, 10  M 4.11 mN, 10  M 3.99 mN; 30 m 10  M 4.29 mN,
10  M 4.05 mN, 10  M 3.94 mN, 10  M 3.84 mN.
Fig. 1
Effect of cumulative concentrations-dependent administration of PACAP1-38 on
the relaxation of basilar and carotid arteries as a function of age (original figure).
Black arrow representing administration of KCl (60 mM); PACAP was
administrated in sequential order: 10 , 10 , 10 , and 10  M. Last
administration was SNP 10  M.
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Original records (Fig. 1 , panel b) show the relaxations of CA to the cumulative
doses of PACAP1-38. It shows that the relaxations substantially decreased
from young (2 m), middle (12 m), and old age (30 m). Steady-state values are
the following: 2 m 10  M 5.71 mN, 10  M 5 mN, 10  M 4.31 mN, 10  M
3.78 mN; 12 m 10  M 6.21 mN, 10  M 5.99 mN, 10  M 5.39 mN, 10  M
4.88 mN; 30 m 10  M 11.21 mN, 10  M 10.77 mN, 10  M 10.28 mN,
10  M 9.55 mN.
Summary data (Fig. 2 ) show that the relaxations of BA to the cumulative
administration of PACAP1-38 significantly, but not substantially, decreased
from young (2 m), middle age (12 m), and old (30 m) age (2 m 10  M −0.26 
± 0.09 mN, 10  M −0.73 ± 0.08 mN, 10  M −0.85 ± 0.12 mN, 10  M
−0.86 ± 0.1 mN; 12 m 10  M −0.24 ± 0.09 mN, 10  M −0.42 ± 0.09 mN,
10  M −0.52 ± 0.13 mN, 10  M −0.76 ± 0.11 mN; 30 m 10  M −0.23 ± 
0.08 mN, 10  M −0.47 ± 0.07 mN, 10  M −0.58 ± 0.04 mN, 10  M −0.68 
± 0.06 mN, N = 8, n = 16, p < 0.05).
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Effect of cumulative concentration-dependent administration of PACAP1-38 on
the relaxation of basilar artery as a function of age (summary data). Data are
means ± standard error of the mean; *p < 0.05 indicates significant changes
between the PACAP 10  and 10  (N = 8, n = 16).
Summary data (Fig. 3 ) show that relaxations of CA to the cumulative doses of
PACAP1-38 significantly and substantially decreased from young (2 m) and
middle age (12 m) to old (30 m) age (2 m 10  M −0.37 ± 0.07 mN, 10  M
−1.08 ± 0.06 mN, 10  M −1.77 ± 0.08 mN, 10  M −2.3 ± 0.12 mN; 12 m
10  M −0.18 ± 0.03 mN, 10  M −0.57 ± 0.04 mN, 10  M −0.98 ± 0.07 mN,
10  M −1.88 ± 0.31 mN; 30 m 10  M −0.13 ± 0.02 mN, 10  M −0.2 ± 0.04
mN, 10  M −0.36 ± 0.06 mN, 10  M −0.83 ± 0.12 mN, N = 8, n = 16, p < 
0.05).
Fig. 3
Effect of cumulative concentration-dependent administration of PACAP1-38 on
the relaxation of carotid artery as a function of age (summary data). Data are
means ± standard error of the mean; *p < 0.05 indicates significant changes
between the PACAP 10  and 10  (N = 8, n = 16), **p < 0.05 indicates
significant changes between the PACAP 10  and 10  (N = 8, n = 16), ***p < 
0.05 indicates significant changes between the PACAP 10  and 10  (N = 8, n = 
16). #p < 0.05 indicates significant changes between 2 and 12 months of age












30 months of age groups (N = 8, n = 16). Xp < 0.05 indicates significant changes
between 12 and 30 months of age groups (N = 8, n = 16).
Age-Dependent Differences in PACAP1-38-Induced
Relaxation of Basilar and Carotid Arteries
To indicate the age-dependent changes in PACAP1-38-induced relaxations, we
calculated the difference between the responses of BA and CA of 30-, 12-, and
2-month-old rats. Summary data in Fig. 4a  show that in BA of various age
groups, there were slight but significant reduction in relaxations to the lower
concentrations (30–2 m 10  M 0.03 ± 0.08 mN, 10  M 0.25 ± 0.02 mN,
10  M 0.27 ± 0.07 mN, p < 0.05), whereas there were no differences in
relaxations to higher concentrations of PACAP1-38 (30–12 m 10  M 0.28 ± 
0.01 mN, 10  M 0.05 ± 0.02 mN, 10  M 0.05 ± 0.08 mN, 10  M 0.07 ± 
0.06 mN; 12–2 m 10  M 0.25 ± 0.04 mN, 10  M 0.21 ± 0.07 mN, 10  M
0.22 ± 0.08 mN, 10–6 M 0.10 ± 0.07 mN, N = 8, n = 16).
Fig. 4
a, b Age-dependent differences in PACAP1-38-induced relaxations of basilar and
carotid arteries (BA and CA). Data are means ± standard error of the mean; #p < 
0.05 indicates significant changes between the delta’s of 2 m–30 m and 12 m–
30 m (N = 8, n = 16). Δp < 0.05 indicates significant changes between the delta’s
of 2 m–30 m and 2 m–12 m (N = 8, n = 16). Xp < 0.05 indicates significant








Summary data in Fig. 4b  show that in responses of CA of various age groups,
there were significant and substantial reductions in relaxations as a function of
age (30–2 m 10  M 0.24 ± 0.04 mN, 10  M 0.88 ± 0.04 mN, 10  M 1.4 ± 
0.05 mN, 10  M 1.46 ± 0.05 mN; 30–12 m 10  M 0.05 ± 0.03 mN, 10  M
0.37 ± 0.05 mN, 10  M 0.62 ± 0.06 mN, 10  M 1.05 ± 0.19 mN; 12–2 m
10  M 0.18 ± 0.04 mN, 10  M 0.5 ± 0.04 mN, 10  M 0.78 ± 0.06 mN,
10  M 0.41 ± 0.19 mN, N = 8, n = 16, p < 0.05). That is, aging reduced
relaxations to PACAP more in CA than in BA (Fig. 4a, b ).








Administration of PACAP1-38 on the Relaxation of Basilar
and Carotid Arteries in Presence of PAC1 Receptor Blocker
(6–38) as a Function of Age
Summary data in Fig. 5a  show that in the presence of PAC1 receptor blocker
(10  M), there was no change in vasomotor response of BA to the cumulative
administration of PACAP1-38 that was not significant, increased from young
(2 m), middle age (12 m), and old (30 m) age (2 m 10  M −0.35 ± 0.44 mN,
10  M −0.42 ± 0.51 mN, 10  M −0.15 ± 0.39 mN, 10  M −0.25 ± 0.44 mN;
12 m 10  M 0.01 ± 0.51 mN, 10  M −0.05 ± 0.53 mN, 10  M −0.09 ± 0.54
mN, 10  M −0.14 ± 0.53 mN; 30 m 10  M −0.15 ± 0.47 mN, 10  M −0.3 ± 
0.51 mN, 10  M −0.35 ± 0.54 mN, 10  M −0.41 ± 0.55 mN, N = 8, n = 16,
p < 0.05).
Fig. 5
a, b Effect of cumulative concentration-dependent administration of PACAP1-38
on the relaxation of carotid artery in the presence of PAC1 receptor blocker (6–










Summary data in Fig. 5b  show that in the presence of PAC1 receptor blocker
(10  M), there was no change in vasomotor response of BA to the cumulative
administration of PACAP1-38 that was not significant, increased from young
(2 m), middle age (12 m), and old (30 m) age (2 m 10  M 0.19 ± 0.39 mN,
10  M 0.35 ± 0.39 mN, 10  M −0.46 ± 0.33 mN, 10  M 0.51 ± 0.36 mN;
12 m 10  M −0.02 ± 0.32 mN, 10  M −0.02 ± 0.39 mN, 10  M −0.02 ± 
0.37 mN, 10  M 0.03 ± 0.38 mN; 30 m 10  M 0.46 ± 0.4 mN, 10  M 0.19 
± 0.26 mN, 10  M −0.25 ± 0.56 mN, 10  M −0.22 ± 0.53 mN, N = 8, n = 16,
p < 0.05).
The Nitric Oxide Donor, Sodium Nitroprusside-Induced










As the original figures show, SNP induced complete relaxations of BA and CA
in each age group, without differences (Fig. 1 ). Summary data show no
significant differences (BA 2 m 98 ± 2 %, 12 m 97 ± 3 % 30 m 99 ± 1 % vs;
CA 2 m 96 ± 4 %, 12 m 98 ± 2 %, 30 m 99 ± 1 %, N = 8, n = 16, p > 0.05,
NS).
Discussion
The novel findings of the present study are the following: (1) PACAP1-38
induced a significantly greater relaxation in isolated CA than that in BA of
young and old rats; (2) the PACAP1-38-induced relaxation of CA significantly
decreased as a function of age, whereas it did not change substantially in BA;
(3) the magnitude of SNP-induced relaxation did not change after PACAP1-38
administration and was not affected by age; and (4) selective PAC1 receptor
blocker completely diminished PACAP1-38-induced vasomotor response in all
age groups of CA and BA. Collectively, these findings suggest that PACAP1-38
has greater vasomotor effect in CA than that in BA and that PACAP-induced
signaling does not interfere with cGMP-mediated relaxation. Furthermore, aging
elicits major impairment in relaxations of peripheral carotid arteries and CA,
whereas aging has no substantial effect on PACAP-induced relaxations of
basilar artery BA, suggesting that the vasomotor role of PACAP is maintained
in cerebral arteries even in old age.
PACAP-Induced Vasomotor Responses of Various Tissues
The polypeptide PACAP has been shown to be a multifunctional molecule
having several biological regulatory roles (Vaudry et al. 2000 ; Tamas et al.
2012 ). For example, PACAP has various hormonal functions in all endocrine
glands; it influences motility and secretion in the gastrointestinal and respiratory
tracts and regulates urogenital physiology (Vaudry et al. 2000 ; Cardell et al.
1991 ; Cheng et al. 1993 ; Ishizuka et al. 1992 ; Botz et al. 2013 ). In addition,
it has been revealed that PACAP has potent vasomotor effects (Suzuki et al.
1993 ; Nandha et al. 1991 ; Hagi et al. 2008 ). Several human studies
demonstrate that PACAP exerts cardiovascular actions partially by the decrease
in mean arterial blood pressure and an increase in blood flow, measured
2014.6.13. e.Proofing
http://eproofing.springer.com/journals/printpage.php?token=XHFE-edcDB64Cw0tTBf0uG4GMt1YSKlDlEYbGMn-uS0 14/23
invasively on beagle dog femoral arteries (Naruse et al. 1993 ; Whalen et al.
1999 ). Previous studies have shown that vessel walls are richly innervated by
PACAP-containing fibers, a high density of PACAP binding sites is present in
arteries (Erdling et al. 2013 ; Baun et al. 2011 ), and PACAP is widely
distributed in 1- to 4-month-old rat brain vessels (Erdling et al. 2013 ). The
blocked vasomotor activity suggests that PACAP 1-38 acts on PAC1 receptor,
which elicits vasorelaxation in a concentration- and age-dependent manner. The
receptor activity is similar in cerebral and extracerebral arteries also.
Studies performed in isolated aortae and coeliac arteries frmm from  rabbit
showed that PACAP elicits relaxation, likely via increasing cAMP level in the
smooth muscle (Wilson and Warren 1993 ). Interestingly, there are no data
regarding the vasomotor effects of PACAP in cerebral and peripheral vessels of
old rats. On the basis of many previous studies showing that aging impairs
vasomotor function (Ivic et al, 2012,  Vamos et al. 2013Tripathy et al, 2010 ),
we hypothesized that the PACAP-induced region-specific vasomotor effects are
substantially modulated by aging. Because PACAP can have multiple effects in
a complex organ, we aimed to characterize the vasomotor responses of
PACAP1-38 in isolated rat BS and CA in young, middle age, and old of rats.
PACAP1-38-Induced Relaxation in Carotid Arteries
In the present study, we found that PACAP1-38 induced concentration-
dependent and substantial relaxations of CA of young rats to the old one, which
were reduced in that of the older rats (Fig 1/b and Fig 3). Others have found
similar results: PACAP1-38 elicits relaxant effect on rabbit aorta and mesenteric
arteries, and also on human and porcine coronary arteries (Warren et al. 1991 ;
Kastner et al. 1995 ). Comparing the magnitude of relaxation within a single
species (rabbit), more prominent response was found in the macrovessels than
the microcirculation (Wilson and Warren 1993 ). It was particularly effective in
skin microcirculation measured in vivo with a laser Doppler flow probe and
shows a particularly sensitive vasodilator response to PACAP (Lissbrant et al.
1999 ). The PACAP1-38-induced relaxation was more prominent in rabbit
coeliac arteries compared to our findings in CA (Wilson and Warren 1993 ).
There are a number of possible explanations for the previous findings that
PACAP induced different relaxations in vessels of different origins, such as
differences in the animal used or origin of vessel or methods used. Thus, in the
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present study, we used one species (rats) and isolated arteries from two
different origin to reduce uncertainties in the interpretation of results and
allowing us to discern the effect of age on the PACAP-induced vasomotor
effects. Interestingly, relaxations were significantly greater in CA than those in
BA, and PACAP-induced relaxations were significantly reduced in CA of older
rats. Our findings with CA are important, because previous studies showed that
these arteries mirror changes that occur in the coronary arteries (Vogel et al.
1999 ).(Rothwell et al. 2001).
PACAP-Induced Relaxations of Basilar Arteries
We found that PACAP1-38 elicited substantially smaller relaxations in BA
compared to CA, suggesting that PACAP1-38 is acting primarily on CAmore
effective in peripheral than cerebal arteries.. In previous studies (Amenta et al.
1991 ; Fahrenkrug et al. 2000 ; Erdling et al. 2013 ), the vascular effects of
PACAP1-38 were investigated in segments of rat middle cerebral artery (MCA)
by pressurized arteriography and in a wire myograph. The authors have found
the same magnitude of concentration-dependent relaxations of the MCA, in
arteries of rat dura, whereas in human meningeal arteries, PACAP1-38 induced
weak relaxations (Arsalan et al. 2013; Baun et al. 2011 ). Others described that
cerebellar arteries isolated from the brain surface were ~1,000-fold less
sensitive to PACAP than the middle meningeal arteries (Syed et al. 2012 )
showing important region specificity. In the present study, we also found
thatdecreases in PACAP1-38-induced relaxation in BA decreaseswere less in
old age than in CA. The magnitude of changes of relaxations was assessed by
subtracting the responses of 2-month-old rats from those of 30-month-old
animals. We found a greater decrease in the magnitude of response in CA, but
not in BA, suggesting that aging affects more the responses of peripheral
carotid arteries and CA than those of the cerebral arteries, such as BA.
AQ1
AQ2
PACAP-Induced Vasomotor Molecular Signaling
Our findingsThe findings of the present study  help to further elucidate the
region-specific PACAP-induced vasomotor responses and their changes in the
healthy aging. It has been demonstrated that the wall of blood vessels is richly
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innervated by PACAP-containing fibers and a high density of PACAP binding
sites is present in arteries (Vaudry et al. 2000 ). Also, it has been shown that
PAC1 receptors are present and located in the cytoplasm of smooth muscle
cells (Erdling et al. 2013 ).In the present study PACAP 6-38 inhibited the
vasorelaxations suggesting that PACAP 1-38 acts on PAC1 receptor and that
the activity of receptors are similar in cerebral and extracerebral arteries. The
present findings of our studies show that PACAP-induced signaling does not
interfere with the direct relaxant cGMP-mediated involve cGMP in mediation
of  relaxation of arteries and aging specifically affects PACAP responses
because SNP-induced responses were not affected by aging.
As shown by previous studies, in arterial vessels, the PACAP-induced dilator
effect is mediated by activating PAC1 receptor on the smooth muscle cell,
followed by activation of adenylate cyclase (Erdling et al. 2013 ; Tamas et al.
2012 ). A previous study (Erdling et al. 2013 ) suggests that activation is via the
stimulation of cAMP production in blood vessels, which modulates L-type
calcium channels in vascular smooth muscle cells through the activation of both
protein kinase A (PKA) and protein kinase C (PKC) mechanisms resulting in
vasodilation (Chik et al. 1996 ). PACAP also stimulates the release of the
prostaglandin PGF  in the wall of the arteries but does not affect other
cyclooxygenase metabolites (Huang et al. 1992 ; Kastner et al. 1995 ). Others
found that PACAP relaxes human pulmonary arteries by opening of KATP and
KCa channels (Bruch et al, 1998).The possible involvement of the endothelium
in the vasodilator activity of PACAP is still not clear: Some reports indicate that
the relaxant effect of PACAP on the rabbit aorta and coronary arteries is
endothelium-independent (Warren et al. 1991 ; Kastner et al. 1995 ), whereas
another study reveals that removal of the vascular endothelium abolishes the
dilatorydilator response induced by PACAP in guinea pig pulmonary arteries
(Cardell et al. 1991 ). More importantly, the effect of age on the PACAP-
induced vasomotor responses are not known.
Potential Roles of PACAP1-38 Signaling Eliciting Relaxation
as a Function of Age
Previous studies described age-related changes in PACAP immunoreactivity
and its protein levels in the gerbil hippocampus (Tripathy et al. 2010 ).




known. In the present study, we observed that the PACAP1-38-induced
vasomotor response shows an age and vessel location dependency. These
findings suggest that aging may induce vessel-specific changes in the functional
availability and/or density of PAC1 receptor. This could be due to the altered
receptor mRNA and protein expression in older age compared to the younger
rats or different activation and internalization of the receptors and/or their
subcellular pathways (cAMP, PKA, PKC, or MLCK) (Boni et al. 2009 ).
Indeed, most previous studies have found that PAC1 receptors possess a
unique feature: The density and distribution of these proteins change as a
function of age. In the present study, we have found that inhibition of PACAP
receptors (Fig. 5a, b ) completely blocked relaxation to PACAP in all age
groups, suggesting that primarily PAC1 receptors are involved in the signaling.
Nevertheless, more studies are necessary to further reveal the vasomotor
effects of PACAP in various age groups. It is important to elucidate whether it
has protective or deleterious effects, since previous studies assigned clinical
significance for PACAP in headache due to prolonged dilation of cerebral
arteries to PACAP (Amin et al. 2012 ). In contrast, other studies demonstrated
increased vascular contractile activity in older age (Ivic et al. 2012 ), when
relaxations to PACAP was less affected.
In conclusion, the novel findings of the present study suggest that PACAP1-38
has a greater dilator effect in peripheral carotid arteries and CA than that in
cerebral basilar arteries and BA. Furthermore, aging elicits major impairment in
the PACAP-induced relaxation of peripheral carotid arteries and CA, whereas
aging has no substantial effect on the relaxation of cerebral basilar  arteries and
BA, suggesting that the vasomotor role ofrelaxations to PACAP is maintained in
cerebral arteries even in old age.
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